<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13206">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01814007</url>
  </required_header>
  <id_info>
    <org_study_id>ZA13-001</org_study_id>
    <nct_id>NCT01814007</nct_id>
  </id_info>
  <brief_title>Multiple Treatment Study</brief_title>
  <official_title>SAFETY EVALUATION OF MULTIPLE COOLSCULPTING TREATMENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeltiq Aesthetics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeltiq Aesthetics</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate if multiple same-day CoolSculpting treatments increase the risk of abnormal
      lipids and liver-related tests.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Evaluation of lipid levels</measure>
    <time_frame>12-weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood draws will be collected at various intervals, after the multiple treatments have been performed, and analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence and severity of all reported adverse events and clinical assessment of any side effects/pain in the treatment area.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Body Fat Disorder</condition>
  <arm_group>
    <arm_group_label>Fat Reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Zeltiq System</intervention_name>
    <description>Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.</description>
    <arm_group_label>Fat Reduction</arm_group_label>
    <other_name>Cryolipolysis</other_name>
    <other_name>Lipolysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female subjects &gt; 18 years of age.

          -  Subject who has been assessed to receive multiple CoolSculpting treatments on the
             abdomen and flanks, defined as follows:

               1. Lower Abdomen - One 60 minute cycle with CoolMax,

               2. Right and Left Flank - One 60 minute cycle per flank, with CoolCurve+ or
                  CoolCore, simultaneously.

          -  Subject has not had weight change exceeding 10 pounds in the preceding month.

          -  Subject with body mass index (BMI) up to 30. BMI is defined as weight in pounds
             multiplied by 703 divided by the square of the height in inches.

          -  Subject agrees to not making any major changes in their diet or lifestyle during the
             course of the study.

          -  Subject has read and signed a written informed consent form.

        Exclusion Criteria

          -  Subject has had an invasive (e.g., liposuction, mesotherapy, abdominoplasty) or
             non-invasive fat reduction and/or body contouring procedure in the area of intended
             treatment within the past 6 months.

          -  Subject needs to administer, or has a known history of subcutaneous injections into
             the area of intended treatment (e.g., heparin, insulin) within the past month.

          -  Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold
             hemoglobinuria.

          -  Subject has a history of hernia in the area(s) to be treated.

          -  Subject is pregnant or intending to become pregnant during the study period (in the
             next 4 months).

          -  Subject is lactating or has been lactating during the past 3 months.

          -  Subject is unable or unwilling to comply with the study requirements, such as blood
             draw.

          -  Subject is currently enrolled in a clinical study of any other unapproved
             investigational drug or device.

          -  Subject has a history of lipodosis or other confounding metabolic diseases.

          -  Subject is taking or has taken medication within the past 3 months which may affect
             the metabolic function.

          -  Patient has a history of diabetes.

          -  Any other condition or laboratory value that would, in the professional opinion of
             the investigator, potentially affect the subject's response or the integrity of the
             data or would pose an unacceptable risk to the subject.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Innovation Research Center</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ed Becker, MD</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bowes Dermatology Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>May 16, 2013</lastchanged_date>
  <firstreceived_date>March 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipolysis</keyword>
  <keyword>Cryolipolysis</keyword>
  <keyword>Fat Reduction</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sphingolipidoses</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
